Prevalence of homologous recombination repair genes alterations in metastatic castration-resistant prostate cancer, a multicentric study.

Date publication

juin 2026

Journal

The French journal of urology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LINDNER Véronique

Tous les auteurs :
Allaume P, Raby M, Nourieh M, Lespagnol A, Tallet A, Péricart S, Tantot J, Lindner V, Decaussin M, Callens C, Descotes F, Allory Y, Rioux-Leclercq N, Kammerer-Jacquet SF, Fromont G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42303208

Résumé

Homologous Recombination Repair (HRR) genes alterations are a resistance mechanism to therapies by taxanes or Androgen Receptor Signalling inhibitors in Metastatic Castration Resistant Prostate Cancer (mCRPC). BRCA-mutated mCRPC patients are eligible to poly adenosine diphosphateribose polymerase inhibitors (PARPi). Therefore, assessing the population-specific prevalence of HRR-related genes alterations is of public healthcare importance.

Mots clés

Castration resistance, Homologous Recombination Repair, Prostate cancer, Targeted therapy, cancer de prostate, résistance à la castration, thérapie ciblée

Référence

Fr J Urol. 2026 06 16;:103148